Immunome discloses merger-related lawsuits and supplemental proxy disclosures

Immunome Inc.

Two securities lawsuits filed by purported stockholders challenging the merger: Weiss v. Immunome (Sept 7) and Thompson v. Immunome (Sept 8).
Eleven stockholder demands and one books-and-records demand received regarding disclosure adequacy in the merger proxy.
Immunome denies wrongdoing but issues supplemental disclosures to avoid litigation costs and potential disruption to the merger.
Disclosures include details on the Transaction Committee, background discussions, discounted cash flow analysis ranges, and Dr. Siegall's recruitment.
Exchange ratio implies Immunome stockholders would own ~55% of the combined company on a fully diluted basis before PIPE and option grants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.